ESMO-BC 2024 - ESMO Breast Cancer Annual Congress
May 15 - May 17, 2024 | BerlinGermany
LARVOL is not affiliated with ESMO Breast Cancer Annual Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 30 titles linked to Trials
IMpassion132 double-blind randomised phase 3 trial of chemotherapy (CT) _ atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)
Adjuvant Endocrine Therapy for Premenopausal Invasive Lobular Carcinoma (ILC): Results from SOFT and TEXT phase III studies
Trastuzumab deruxtecan (T-DXd) vs Treatment of Physician's Choice (TPC) in Patients (pts) With HER2+ Metastatic Breast Cancer (mBC) Previously Treated With Trastuzumab Emtansine (T-DM1): Updated Overall Survival (OS) Results of the Randomized, Phase 3 DESTINY-Breast (DB-)02 Study
Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial
Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase 3 PANTHER trial
Neoadjuvant study of 12 months of Abemaciclib plus Letrozole vs. Chemotherapy in HR+/HER2_ highly proliferative (Ki67_20%) breast cancer: CARABELA (GEICAM/2019-01) Trial
TROPION-Breast04: Phase (Ph) 3 study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC)
Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): results of the international phase II DOLAF trial.
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable / metastatic HR+/HER2- breast cancer (BC): Additional safety analysis from TROPION-Breast01
SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC)
Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial
Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: a translational analysis
Plasticity marker FOXC1 expression is a superior predictor of Adjuvant Tamoxifen + Chemotherapy efficacy in reducing disease recurrence and all-cause mortality in ER+LN- Breast Cancer: Validation in the SCAN-B Prospective Study (NCT02306096)
PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy - a biomarker study of the LORELEI trial
Circulating cytokines to predict pCR to neoadjuvant chemotherapy and nivolumab for ER+/HER2- BC: analysis of the phase 2 GIADA trial